Navigation Links
Bacteria in small sea life yield new way to make potential cancer drugs

Researchers led by a University of Utah medicinal chemist have developed a novel method to make drugs for cancer and other diseases from bacteria found in sponges and other small ocean creatures.

In a study published Sunday, Nov. 5, in Nature Chemical Biology online, researchers examined symbiotic bacteria that live only in sea squirts and other marine life. These bacteria are responsible for making a wealth of chemicals, which accumulate in the tissues of sea squirts and may help to defend them against predators. Many of these chemicals have anticancer properties, but harvesting them in quantities for large-scale testing and production has been impractical.

The new method uses genetic pathways in the bacteria to produce the small chemicals and to manipulate them to invent new potential drugs. The ability to make these chemicals in the laboratory opens myriad possibilities for developing drugs to fight cancer, HIV, and other diseases, according to Eric W. Schmidt, Ph.D., assistant professor of medicinal chemistry at the University of Utah College of Pharmacy and senior author on the study.

"This represents a new way of attacking the problem," Schmidt said. "We're hoping we can use this to find a way to make natural molecules of compounds through single mutations in DNA."

To synthesize natural compounds, researchers have traditionally made them in the lab using labor-intensive routes. More recently, researchers have begun to use genes to make small molecules within laboratory strains of bacteria. This genetic synthesis method is complicated because it's still difficult to understand how changing genes can lead to changes in small drug molecules.

"The promise of genes is that you can access the tremendous natural diversity of the world's organisms to find new natural compounds for human health," Schmidt said. "You can also use genetic engineering to modify these compounds and invent new drugs to target human diseases."
'"/>

Source:University of Utah Health Sciences Center


Page: 1 2

Related biology news :

1. Bacteria collection sheds light on urinary tract infections
2. Solution to Pollution: New Bacteria Eats Toxic Waste
3. The Bacterias guide to survival
4. UF Researchers Map Bacterial Proteins That Cause Tooth Loss
5. Bacterial genome sheds light on synthesizing cancer-fighting compounds
6. Where Bacteria Get Their Genes
7. Bacteria feed on smelly breath (and feet)
8. New insight into autoimmune disease: Bacterial infections promote recognition of self-glycolipids
9. Bacteria use hosts immune response to their competitive advantage
10. Say what? Bacterial conversation stoppers
11. Bacteria are key to green plastics, drugs
Post Your Comments:
Breaking Biology Technology:AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia 2AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia 3Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc. 2Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc. 3WuXi PharmaTech Selects Labcyte POD(TM) 810 Platform for High-Throughput Screening 2RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 2RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 4RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 5RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 6